Answers are grounded in this paper and cite their sources.
This study reports docking analysis and performance of catechin and its derivatives in activating the SIRT1 and SIRT3 protein for the treatment of COVID-19. Val-412, Asp-348, Pro-271, and Ser-442 are interactions involved in hydrogen bonding and Ile-316, Ala 262, Ile-347, Val-445, Phe-297, His 363 are interactions involved in hydrophobic bonding between the various ligands and SIRT1 protein. ILE-111, Val-173, Asp-112, Phe-38 are interactions involved in hydrogen bonding and Phe-38, Ala-27, Ile-111, His-129, Phe-38 are involved in hydrophobic bonding between the various ligands and SIRT3 protein. Catechin gallate and epigallocatechin gallate show promising potential as SIRT1 activators as observed by their binding affinity ΔG=-10.9 kcal/mol and ΔG=-10.6 kcal/mol, which are lower than the binding affinity of the standard therapeutic moiety resveratrol (ΔG=-9.0 kcal/mol). All catechins show promising potential as SIRT3 activators, as revealed by their binding affinities, which are lower than the binding affinity of the standard therapeutic moiety resveratrol (ΔG=-8.4 kcal/mol). Amongst all the catechins, catechin gallate shows 61.53% binding site similarity with the native ligand in the case of SIRT1 protein. Amongst all the catechins, epicatechin and epigallocatechin show 100% binding site similarity with the native ligand for the SIRT3 protein. Therefore, we suggest that catechins can serve as SIRT1 and SIRT3 activators, which may prove to be a possible therapy for COVID-19.
No takes yet. Share an insight, caveat, or question.
Khan et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: